Plasma and Pleural Fluid Pharmacokinetics of Erlotinib and its Active Metabolite OSI-420 in Patients With Non–Small-Cell Lung Cancer With Pleural Effusion-Reference-Cited by-同舟云学术

Plasma and Pleural Fluid Pharmacokinetics of Erlotinib and its Active Metabolite OSI-420 in Patients With Non–Small-Cell Lung Cancer With Pleural Effusion

Published:2011-09 Issue:5 Volume:12 Page:307-312
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Masago Katsuhiro,Togashi Yosuke,Fukudo Masahide,Terada Tomohiro,Irisa Kaoru,Sakamori Yuichi,Kim Young Hak,Mio Tadashi,Inui Ken-ichi,Mishima Michiaki

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. Epidermal growth factor receptor targeting in cancer;Mendelsohn;Semin Oncol,2006

2. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial;Ranson;J Clin Oncol,2002

3. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer;Baselga;J Clin Oncol,2005

4. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

5. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen;Johnson;Clin Cancer Res,2005

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Osimertinib-induced biventricular cardiomyopathy with abnormal cardiac MRI findings: a case report;Cardio-Oncology;2023-10-31

2. Efficacy of hyperthermic intrathoracic chemotherapy for initially diagnosed lung cancer with symptomatic malignant pleural effusion;Scientific Reports;2023-07-26

3. Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spaces—A Review;Pharmaceutics;2023-01-10

4. Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance;Cancers;2020-11-10

5. Non-significant efficacy of icotinib plus pleurodesis in epidermal growth factor receptor positive mutant lung cancer patients after malignant pleural effusion drainage compared to icotinib alone;Journal of Thoracic Disease;2020-05